

**Pancreatic Cancer**

**Second Guideline Development Group (GC) meeting**

11 April 2016

Committee Room 1, RCOG, London

**GROUP MEMBERSHIP & ACTION LIST**

<b>GC Members</b>	
Professor John Primrose (JP)	Anna Jewell (AJ)
Professor John Neoptolemos (JN)	Laura McGeeney (LM)
Mark Callaway (MCal)	Dr Somnath Mukherjee (SM)
Dr Margred Capel (MCal)	Dr Kofi Oppong (KO)
Mr Richard Charnley (RC)	Mr Derek O'Reilly (DOR)
Dr Pippa Corrie (PC)	Philip Whelan (PW)
Dawn Elliot (DE)	Suzanne Joharchi (SJ)
Lesley Goodburn (LG)	
<b>NGA staff</b>	
John Graham (JG)	Ferruccio Pelone (FP)
Angela Bennett (AB)	Elise Hasler (EH)
Susan O'Connell (SOC)	James Hawkins (JH)
Alexandra Hellyer (AH)	
<b>NICE staff</b>	
Tom Feist (TF)	
<b>Apologies</b>	
Professor Fiona Campbell (FC)	Katie Perryman Ford (KPF)

**REPORTS OF DISCUSSIONS AT THE MEETING**

**1. Introductions**

JP welcomed everyone to the 2nd meeting of the Pancreatic Cancer GC. Apologies were noted from Fiona Campbell and Katie Perryman Ford.

**2. Declarations of Interest**

The following declarations of interest were declared prior to the meeting:

Mark Callaway	Received an honorarium from Succinct in March 2016 for co-chairing a round table discussion about the role of transarterial chemoembolization for hepatocellular carcinoma. This will be used to write an article for Bayer UK.	Personal financial non-specific	No action needed
Dr Somnath Mukherjee	Chief investigator for the ARC II trial (A Phase II study in patients with locally advanced pancreatic carcinoma: Akt-inhibition by Nelfinavir plus chemoradiation with gemcitabine and cisplatin). Not involved in designing the trial protocol as took over as CI towards the end. Funded by University of Oxford.	Non-personal financial specific	No action needed as not involved in designing trial protocol and trial not funded by industry

**Web minutes of 2nd Pancreatic Cancer GC meeting on 11<sup>th</sup> April 2016**

	This study is just about to be published. [1.4.16]		
Dr Somnath Mukherjee	Co-investigator for ESPAC-5F Four arm, prospective, multicentre, randomised Phase II trial of immediate surgery compared with neoadjuvant chemotherapies and neoadjuvant chemoradiotherapy. Funded by Cancer Research UK	Non-personal financial specific/non-specific	No action needed as not involved in designing trial protocol and trial not funded by industry
Dr Somnath Mukherjee	Co-applicant (wrote the clinical context information) on successful pre-clinical grants from Pancreatic Cancer UK to look at novel imaging in mice	Non-personal financial non-specific	No action needed
Dr Somnath Mukherjee	Assisted Pancreatic Cancer UK with development of patient information resources and their patient charter	Non-financial specific	No action needed
Dr Somnath Mukherjee	Joint chief applicant on request for funding from CRUK for the SCOPE2 trial (oesophageal cancer)	Non-personal financial non-specific	No action needed
Anna Jewell	Pancreatic Cancer UK are funding a project being led by Derek Manas to collect data on the use of IRE in pancreatic cancer. As part of this project, has been involved in a couple of meetings and teleconferences with Angiodynamics (manufacturers of equipment used to deliver IRE). Will not participate in any more of these meetings for the duration of the guideline	Non-financial personal specific/non-specific	No action needed
Professor Fiona Campbell	Collaborator providing pathology input to European Study Group for Pancreatic Cancer Trial 4 prospective sample collection - ESPAC 4T. Funded by CRUK [1.4.16]	Non-personal financial specific/non-specific	No action needed as no supervisory responsibility for the trial
Professor Fiona Campbell	Collaborator providing pathology input to Whole Genome Sequencing of Pancreatic Cancers from Patients Selected from the ESPAC Trials to Identify Novel Pathways and Networks Determining Response to Chemotherapy and Chemoradiotherapy. Funded by CRUK [1.4.16]	Non-personal financial non-specific	No action needed as no supervisory responsibility for the trial
Professor Fiona Campbell	Collaborator providing pathology input to European Study Group for Pancreatic Cancer Trial 5F prospective sample collection – ESPAC-5FT. Funded by CRUK [1.4.16]	Non-personal financial specific/non-specific	No action needed as no supervisory responsibility for the trial
Professor Fiona Campbell	Collaborator providing pathology input to Impact of tumour-associated myeloid cells on cancer stemness and chemotherapy-resistance. Funded by North West Cancer Research Fund [1.4.16]	Non-personal financial non-specific	No action needed as no supervisory responsibility for the trial
Professor Fiona Campbell	Collaborator providing pathology input to Validation of serum biomarkers for pancreatic cancer detection. Funded by North West Cancer Research [1.4.16]	Non-personal financial specific/non-specific	No action needed as no supervisory responsibility for the trial
Professor Fiona Campbell	Collaborator providing pathology input to MicroRNA profiling in pancreatic stellate cells: validation and assessment of potential to predict response to treatment. Funded by Pancreatic Cancer UK [1.4.16]	Non-personal financial specific/non-specific	No action needed as no supervisory responsibility for the trial
Professor Fiona	Collaborator providing pathology input to Stratification of adjuvant chemotherapeutic response to allow	Non-personal financial non-specific	No action needed as no supervisory responsibility for the

## Web minutes of 2nd Pancreatic Cancer GC meeting on 11<sup>th</sup> April 2016

Campbell	personalised choice of pyrimidine prodrug: based on levels of transporters and enzymes involved in initial metabolism. Funded by CRUK [1.4.16]		trial
Professor Fiona Campbell	I collect pancreatic cancer tissue samples for a PhD student, who is funded jointly by RedX Oncology & the Pancreas Biomedical Research Unit, University of Liverpool [1.4.16]	Non-personal financial specific	No action needed
Laura McGeeney	With two other dieticians, wrote a patient information sheet on PERT (approx. 5 years ago) which was formatted, printed and distributed by Abbot and Mylan Pharmaceuticals. Companies has no input into the content of the information sheet	Non-financial personal specific	No action needed
Mr Derek O'Reilly	Organiser of the Manchester Pancreatic Cancer Symposium, due April 14th 2016. Commercial sponsors: Mylan, Angiodynamics, Pancreatic Cancer UK, Medtronic, Pharmacyclics, OncoDNA. [8.4.16]	Non-personal financial specific	No action needed as companies only provide financial support for events – no input into content
Mr Derek O'Reilly	Member of Medical Advisory board for the charity, Pancreatic Cancer UK (no payment) [8.4.16]	Non-financial personal specific	No action needed
Mr Derek O'Reilly	Chief investigator: Prehabilitation in HPB Surgery: An Integrated program of Nutritional support; Exercise and improved general well-being; and Screening for anxiety and depression, right across the four phases of: Prehabilitation, Enhanced recovery, Recovery/reablement and Living with and beyond cancer. Funded by Macmillan [8.4.16]	Non-personal financial non-specific	No action needed
Mr Derek O'Reilly	Chief investigator: ACE Manchester Cancer Jaundice Pathway. Funded by NHS England/CRUK [8.4.16]	Non-personal financial non-specific	No action needed
Mr Derek O'Reilly	Principal investigator and Trial Steering Committee member: PANasta trial: Cattall Warren versus Blumgart techniques of panreatico-jejunostomy following pancreato-duodenectomy – a double blinded multi centred trial. Funded by National Cancer Research Institute [8.4.16]	Non-personal financial specific	No action needed as no supervisory responsibility in the trial
Mr Derek O'Reilly	Principal investigator ESPAC-5: Four arm, prospective, multicentre, randomised, feasibility trial of immediate surgery compared with neoadjuvant chemotherapies and neoadjuvant chemoradiotherapy. NCRI funded. [8.4.16]	Non-personal financial specific	No action needed as no supervisory responsibility in the trial
Mr Derek O'Reilly	National Confidential Enquiry into Patient Outcomes and Death (NCEPOD): Currently, National Clinical Co-ordinator (Surgery), responsible for the Acute Pancreatitis Study, due for launch in July 2016. [8.4.16]	Non-personal financial specific	No action needed
Mr Derek O'Reilly	Pathway Clinical Director for HPB, Manchester Cancer. Manchester Cancer is an integrated Cancer system for the 10 hospital Trusts serving the 3.5 million people in the Greater Manchester & Cheshire region. [8.4.16]	Non-personal financial non-specific	No action needed

## Web minutes of 2nd Pancreatic Cancer GC meeting on 11<sup>th</sup> April 2016

The GC were reminded that if they take on any new interests, these must be declared as soon as they happen so that the necessary action can be taken.

### 3. Discussions

The GC drafted and agreed a PICO table for questions 1, 2, 3c, 3d, 4, 5f, 6. They also discussed the priority for economic investigation for each of these questions.

The GC reviewed and signed off the review protocols for questions 5a, 5e and 5g

### 4. Close of meeting

JP thanked the GC for their input to the meeting, reminded them that the next meeting would be on **Wednesday 25<sup>th</sup> may 2016**, Council Chamber, RCOG, 27 Sussex Place, London and closed the meeting.